Prevention therapeutics of dementia.
In the absence of effective drugs for Alzheimer's disease (AD) and a validated roadmap or guideline for drug development, it is important to consider some of the limitations currently hampering AD drug development and some general principles for moving forward. This paper will address current barriers to developing drugs for AD, and offer new considerations for accelerating drug discovery, development, and clinical trials.
Schneider
Lon S
LS
Department of Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. lschneid@usc.edu
D000544:Alzheimer Disease / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D012107:Research Design